Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teijin gains Japanese rights to NeuroSigma's Monarch eTNS device for ADHD

Executive Summary

NeuroSigma Inc. granted Teijin Pharma Ltd. exclusive Japanese marketing rights to its Monarch external trigeminal nerve stimulation (eTNS) system for the non-drug treatment of attention deficit hyperactivity disorder (ADHD). As part of the agreement, Teijin also gains patent rights in Japan to NeuroSigma's TNS technology in the ADHD indication.
Deal Industry
  • Medical Devices
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies